Blog

Over the past few weeks, we've seen a bunch of new publications come through from customers highlighting the capabilities of our many products. These include two studies using some of our highly touted pain research antibodies in migraine and neuropathic pain research. Additionally, one of our primary human cell types was utilized in pancreatic cancer research. You can explore all citations using Neuromics products here.

In the first piece of research, migraine researchers used two of our Neuropeptide Y (NPY) receptor antibodies. The investigators injected mice with glyceryl trinitrate (GTN) in the medial habenula (MHb) to produce a migraine mouse model. Upon microinjections of NPY, the signs of migraine decreased in the GTN mice. Using our Rabbit Polyclonal NPY Y1 Receptor Antibody (cat. RA24506) and Rabbit Polyclonal NPY Y2 Receptor Antibody (cat. RA14112), the scientist observed activation of NPY Y1 receptors, but not NPY Y2 receptors.

Image: Immunofluorescent staining showing the expression of the Y1 receptor (cat. RA24506) and Y2 receptor (cat. RA14112) in the MHb of GTN mice after microinjections of NPY.

As IBA Lifesciences US distributor, Neuromics equips the American market with the very best protein and cell isolation tools, including an assortment of peptides for T-cell stimulation. These peptides are synthesized to activate antigen-specific CD8+ T-cells, enabling infectious diseases, cancer, and autoimmune research, among other areas. They are currently being used by many large pharmas and biotechs in their projects.

Image: Peptide for T-cell stimulation.

The most popular peptides include the NY-ESO-1 peptide SLLMWITQV (cat. 6-7013-901), Ovalbumin peptide SIINFEKL (cat. 6-7015-901), and WT 1 peptide RMFPNAPYL (cat. 6-7019-901). We also have a number of options for SAR-CoV-2 research. You can check them all out here.

We often highlight the countless areas of study that our antibodies can help researchers. We encourage you to check out all our primary antibodies here along with the many applications they've been used for here.

Now, the three most prominent and common uses for our antibodies are in cancer, neuroscience, and pain research. Well, what do you know? Already this month, new research has been released utilizing our antibodies in those three corresponding areas. We'd like to highlight those studies below.

Image: Staining of various glioblastoma cell lines with Neuromics Humanin antibody (cat. RA19000).

In the first study, Korean researchers used our Humanin rabbit polyclonal antibody (cat. RA19000) to study glioblastoma progression. In their release of preliminary research, the investigators found humanin to encourage glioblastoma progression via the integrin alpha V (ITGAV)–TGF beta (TGF) signaling axis. Read the full publication here.

Thanks to the growing number of researchers using our fetal bovine serum (FBS) products, our FBS is being cited in publications on an increasingly frequent basis. In the last week alone, our FBS has popped up in three new studies that demonstrated the versatility of our FBS options. You can explore all our FBS references here.

In the first publication, investigators from Hendrix college used our Premium Imported FBS (cat. FBS002) to culture COS-7 cells. The researchers wanted to better understand how the cancer cell line avoids ferroptosis. Check out the full publication here.

Scientists also utilized our Premium Imported FBS (cat. FBS002) in the second publication to culture C6 rat glioma cells. The researchers from the University at Buffalo were comparing various quantitative phase imaging (QPI) techniques. Learn more here.

In the final study, researchers used our Heat Inactivated Premium USA Origin FBS (cat. FBS001-HI) in cervical cancer research. With our FBS, the investigators cultured two cervical cancer cell lines, DoTc2 and C-33-A. They found that by knocking down HOTAIR in the cells, metastasis of the cells was impaired. Read the study here.

Since their introduction, our Human Brain Microvascular Endothelial Cells (HBMECs) (cat. HEC02) have been one of our most popular cell types. In the past two years alone, they've been utilized in published glioblastoma, cerebral cavernous malformation (CCM), diabetes, and COVID-19 research. We encourage you to check out all publications using these cells here.

Image: HBMECs stained with Claudin-5

And now, this past month, our HBMECs were cited in newly published hypertension research. Researchers from Albert Einstein College of Medicine were investigating miR-4432, a small nucleic acid, as an inhibitor to fibroblast growth factor binding protein 1 in HBMECs. They found that miR-4432 reduces endothelial oxidative stress, which is a key feature of hypertension. They suggest miR-4432 to be further studied to better understand its role in endothelial dysfunction. Read the full publication here.